AIDS.GOV | SERVICE LOCATOR | SEARCH

BLOG.AIDS.GOV

MENU

NIH

NIH’s Dr. Carl Dieffenbach Shares Science Highlight from Second Day of AIDS 2014

fauci_special_session

The second day of the 20th International AIDS Conference (AIDS 2014) in Melbourne, Australia was filled with scientific findings shared by researchers from around the world. We caught up again with Dr. Carl Dieffenbach, Director of the Division of AIDS at NIH’s National Institute of Allergy and Infectious Diseases (NIAID), and asked him to reflect…

NIH’s Dr. Carl Dieffenbach Looks Ahead to Key Topics to be Explored at AIDS 2014

Carl Dieffenbach Day 1 AIDS 2014

As the 20th International AIDS Conference (AIDS 2014) opened in Melbourne, Australia on Sunday, July 20, 2014, we had the chance to speak with Dr. Carl Dieffenbach. He’s the Director of the Division of AIDS at NIH’s National Institute of Allergy and Infectious Diseases (NIAID). During our brief conversation, Dr. Dieffenbach reflects on the conference theme, “Stepping…

” We have the aspiration of a cure”: Dr. Anthony Fauci speaks to AIDS.gov about the Mississippi Baby

Fauci

“We have better treatments, we have the aspiration of a cure, and we have prevention, particularly in the form of a vaccine. So the research agenda has a lot of possibilities and we are still striving…”- Dr. Anthony Fauci Last Friday, July 11, we sat down with Dr. Anthony Fauci, Director of the National Institutes…

Interview with Dr. Anthony Fauci on “Mississippi Baby”

Dr. Fauci

In an important announcement yesterday, Thursday, July 10, the National Institutes of Health (NIH) reported that the child known as the “Mississippi Baby”—an infant seemingly cured of HIV after treatment had been initiated within hours of birth—now has detectable levels of HIV after more than two years of not taking antiretroviral therapy without evidence of the…

“Mississippi Baby” Now Has Detectable HIV, Researchers Find

nih logo

The child known as the “Mississippi baby”—an infant seemingly cured of HIV that was reported as a case study of a prolonged remission of HIV infection in The New England Journal of Medicine last fall—now has detectable levels of HIV after more than two years of not taking antiretroviral therapy without evidence of virus, according to the pediatric…

National HIV Testing Day, June 27, 2014

NIH logo

Transmission of HIV continues at an unacceptably high rate, and drug use plays an important role—both through exposure to infected body fluids among injection drug users and through the lowered inhibition and risky sexual behaviors that all forms of drug use facilitate. Almost 1.1 million Americans are currently living with the HIV virus, and nearly…

NIH Seeks Applications for HIV and Viral Hepatitis Co-Infection Research Funding

Ronald Valdiserri

The National Institutes of Health (NIH) recently released two funding opportunity announcements (FOAs) to support multidisciplinary studies of HIV and viral hepatitis co-infection. The opportunities were issued under NIH’s R01 or Research Project Grant program and R21 or Exploratory/Developmental Research Grant program. NIH notes that the FOAs were informed by priority areas in the Action…

NIDA 2014 Avant-Garde Award for HIV/AIDS Research

NIDA arp

This week, the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, announced the 2014 Avant-Garde Awards for HIV/AIDS research. According to a NIDA press release, the awards offer hope in battling HIV infection and improving long-term outcomes in HIV-infected drug users. With proposals ranging from enhancing the immune system’s ability…